Project Grant R01HL172859
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$616K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This federal Project Grant award in the amount of $2,803,961 was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a multi-year research effort by Northwestern University to investigate the integrated mechanisms underlying primary graft dysfunction and chronic lung allograft dysfunction following lung transplantation. The research is structured across four interrelated projects that aim to: 1)...
This federal Project Grant award, with a total funding amount of $2,323,927.00 over the period of July 15, 2024 to June 30, 2028, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to understand the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to utilize single-cell RNA sequencing, lineage...
The federal Project Grant award R01HL171164, totaling $786,147.00, was issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports research to investigate the mechanistic links between hypoxia (oxygen deficiency), aberrant lactate generation and shuttling, and their direct impact on promoting pro-fibrotic phenotypes in lung fibroblasts, which are critical to the pathobiology of progressive fibrotic lung...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $277,610 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant titled "Determining the Role of TP53 Regulation in Alveolar Epithelial Transitional Cell State, and the Contribution of Alveolar Epithelial Transitional Cell State to Pulmonary Fibrosis" aims to uncover the mechanisms that regulate alveolar...
This federal Project Grant award, valued at $313,632.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 5-year research project led by Dr. Joseph Cooley at National Jewish Health in Denver, Colorado. The project aims to investigate how interleukin-6 (IL-6) promotes resistance to apoptosis (programmed cell death) in lung fibroblasts, and to explore therapeutic strategies targeting the IL-6-BCL-2...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key research objectives are to: 1) study how epithelial cell-derived heparin-binding epidermal growth factor regulates fibrosis and interacts with myeloid cells, 2) uncover mechanisms for impaired innate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $798,958 to Northwestern University to conduct research on the mechanisms driving chronic lung allograft dysfunction (CLAD) after lung transplantation. The research aims to determine if early primary graft dysfunction (PGD) following transplantation induces chronic activation of the integrated stress response (ISR) in the airway...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Tulane University. The grant, awarded on June 5, 2025, will support research to investigate the metabolic requirements and survival mechanisms of lung and nasal tissue-resident memory CD4+ T cells, and their interactions with lung fibroblasts, to enhance the understanding of pulmonary host defenses against respiratory pathogens. The research...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to support research on "Adapting Cell-Based Therapies for the Treatment of Pulmonary Fibrosis." The award period runs from July 1, 2024, to November 30, 2026. As a prominent academic medical center and research...
This federal Project Grant award of $464,121 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop peptide-based treatments for pulmonary fibrosis. The award will enable The Medical University of South Carolina to test identified peptides derived from collagen XVIII in preclinical models of lung fibrosis and identify a lead candidate for further characterization, dose optimization, and potential...